1
While the primary purpose of SARA is to assess and monitor health services readiness, we show 21 that it can also be an important resource for answering complex research and policy questions 22 requiring multivariate analysis. 23 WHO has called for an 80% availability target for EM-NCD as part of a Global Action Plan, 56 making EM-NCD a global priority.[9] However, aggregate estimates of availability at the 57 country level may disguise stark disparities. To our understanding, the extent to which disparities 58 for EM-NCD availability exist within individual LMIC has not previously been studied. 59
60
We sought to develop a scalable strategy for identifying within-country availability disparities 61 from routinely collected data that could be compared across multiple LMIC. The WHO Service 62 Availability and Readiness Assessment (SARA) is a widely endorsed methodology used to 63 collect health facility-level data on essential medicines, technologies, and human resources. In this analysis, we use SARA data to model internal disparities in the availability of EM-NCD 71 in Uganda. Our objective was to model meaningful associations between EM-NCD availability 72 and facility-level characteristics in a sample of Ugandan health facilities. While the primary 73 purpose of SARA is to assess and monitor health services readiness rather than produce ready-to-74 analyze data for research, we show that SARA can also be an important resource for answering 75 more complex research and policy questions using statistical methods. 76
77
Methods 78
Study Design and Setting 79
In 2013, the Ugandan Ministry of Health used the WHO SARA methodology to survey 209 80 health facilities in 10 districts. Healthcare in Uganda, a low-income country with a growing NCD 81 burden [16] , is delivered in three sectors: public, private-not-for-profit (PNFP), and private-for-82 profit (PFP). Within each sector, health facilities are divided into levels. These include health 83 center (HC) I, II, III, IV, general hospital, and regional/national referral hospital. Each facility 84 type varies by population served, functionality, and leadership. The HC-I level represents the 85 community health worker program rather than facility-based services, and thus is not included in 86 the SARA sampling. While the complete SARA dataset for Uganda includes 13 national and regional referral 96 hospitals, we excluded these facilities from our analysis. These referral facilities were sampled 97 from outside the 10-district geographic frame of the other 196 facilities, which posed problems 98 for modeling several predictor variables of interest. After excluding the referral hospitals, 196 99 facilities remained, including HC-II, HC-III, HC-IV, and general hospitals. 100 101
Outcome Variable 102
The 2013 Uganda SARA collected availability data on 20 EM, called "tracer medicines." We 103 identified 10 of these tracer medicines as EM-NCD. All but one of these, simvastatin, also 104 appear on the Uganda Essential Medicines List (EML), which designates the lowest-level health 105 facility at which each medicine is expected to be stocked ( Table 1) . The outcome variable, EM-106 NCD availability, was measured as a count score of these medicines ranging from 0 to 10. The 107 score represents how many of the ten EM-NCD a particular facility had in stock on the day of the 108 SARA survey. South region incudes Kampala, the capital city. We then assigned each facility to a region 131 according to its recorded district in the SARA dataset. Because Kampala is generally 132 acknowledged to have the greatest concentration of medical resources, we used the South region 133 was used as the reference region. 134 135 Finally, each facility in the SARA data is identified by its managing authority, or sector. These 136 include public, PNFP, or PFP, as defined above. In the current analysis, public facilities are the 137 reference category to which PNFP and PFP facilities are compared. The remaining facilities were 138 coded as HC-II, HC-III, HC-IV or General Hospital. HC-IVs offer the most services outside 139 hospitals, while HC-II facilities offer the fewest services. 140 141 Analysis 142
We fit a series of Poisson regression models using the GENMOD procedure in SAS University 143 Edition (SAS Institute, Inc.). Beginning with a baseline model predicting NCD score by basic 144 amenities domain score, we added independent variables hypothesized to associate with NCD 145 score in a stepwise fashion. With the addition of each new independent variable, we assessed 146 whether model fit was improved relative to the increased number of parameters using the Akaike 147 information criterion (AIC). If model fit improved with the addition of a variable, we retained 148 the variable and added the next one. Using this forward selection strategy, we reached a full 149 "saturated" model. We then used backward elimination to remove independent variables with 150 non-significant parameter estimates, limited contribution to model fit, or limited clinical 151 significance until we reached our final model. All analyses were scaled to correct for over- was the beclomethasone inhaler, which was only present at 3 of 196 (1.5%) facilities. The most 180 widely available medicine, amitriptyline, was present at 93 facilities (48%). Presence of a given 181 EM-NCD did not strongly correlate to the level facility at which it was expected. For example, 182 ACE inhibitors were expected only in referral hospitals but were present at 33 lower-level 183 facilities (17%). Conversely, injectable insulin was expected at lower-level facilities but was 184 only observed in 11% (22) of facilities. 185 
Main Results 191
In bivariate analyses, region, facility type, managing authority, availability of HCT, and 192 availability of HIV care were significantly associated with EM availability (Table 2 ). In the 193 preferred multivariate model (Table 3) The facility type parameter estimates indicate that general hospitals had EM-NCD availability 218 scores nearly twice as high as the lowest level facilities (98% higher, p=.004). HC-IV facilities 219 performed even better than general hospitals, with EM-NCD scores 105% higher than HC-II 220 (p=.002). On average, HC-III do not have significantly greater EM-NCD availability than HC-II; 221 these two facility types were the least likely to have any EM-NCD essential medicines on hand at 222 all. 223 224 On average, and adjusting for the other predictors, facilities in the North and East have EM-NCD 225 availability scores 34% lower (parameter estimate = -0.4217, p = 0.015) and 38% lower 226 (parameter estimate = -0.4782, p = 0.003), respectively, than facilities in the Kampala region. 227
Finally, the two dichotomous variables indicating the availability of different types of HIV-228 related services indicate a complex set of interrelationships between HIV/AIDS services and the 229 availability of essential medicines for NCDs. Offering HIV care and support services was 230 associated with 35% lower average EM-NCD counts (parameter estimate = -0.4340, p = 0.006). 231
However, offering HIV counseling and testing was associated with 57% higher EM-NCD counts 232 (parameter estimate = 0.4530, p = 0.048). 233
234

Other Analyses 235
Due to concerns about sparse data, we considered and rejected a zero-inflated Poisson model. 236
While a zero-inflated model was not appropriate in the case of Uganda, researchers interested in 237 using SARA data to analyze health systems where some types of facilities are expected to never 238 have any essential medicines available should consider these types of mixed models. Other 239 models that were considered and rejected, including a multilevel mixed model, are described in 240 the Appendix. 241 242 Discussion 243
Our findings support previous work that demonstrates that Ugandan health facilities are poorly 244 prepared to address the growing burden of NCD. [12, 16, 18] We extend this previous work by 245 identifying and quantifying clear within-country disparities in preparedness. We found 246 significant associations between EM-NCD availability and geographic region, managing 247 authority, health facility type, and the range of HIV services. The availability of EM-NCD was 248 substantially higher in PFP facilities than in public facilities and strikingly lower in the North 249 and East regions. Availability of EM-NCD had a mixed relationship to availability of care and 250 counseling for HIV. On the one hand, facilities that offer HIV care and support had lower 251 average EM-NCD availability. However, facilities that offer HIV counseling and testing were 252 associated with 57% higher EM-NCD availability counts. 253 254 Our model suggests that PFP health facilities are responding most quickly to the burgeoning 255 need for EM-NCD. Adjusting for the other variables such as facility type and amenities, PFP 256 facilities had EM-NCD counts nearly twice as high as public facilities. However, PFP facilities 257 are often out of financial reach for most Ugandans. For example, a controller medicine for 258 asthma, such as beclomethasone inhaler, costs approximately seven US dollars, the equivalent of 259 three days wages, based on the per capita gross domestic product. 260 261 Facility type also had a sizable effect on EM-NCD availability in our model, though the facilities 262 offering the most sophisticated services--general hospitals--do not necessarily have the greatest 263 availability. Adjusting for region and other facility characteristics, the HC-IV facilities 264 outperformed even general hospitals. Primary care HC-II and HC-III facilities, on the other hand, 265 are likely to have few, if any, EM-NCD on hand. It may not be surprising that facility type has a 266 significant effect on predicted EM-NCD count. However, consistent, long-term access to these 267 medicines is critical for the effective and uninterrupted treatment of patients with chronic 268 conditions. Individual countries adapt the WHO Essential Medicines List (EML) based on local 269 disease prevalence, cost-effectiveness, and other national priorities. Countries also determine the 270 lowest-level health facilities that are expected to stock each EM (see Table 1 ). Based on 2014 271 census data and hypertension prevalence data from the 2014 National Non-Communicable 272 Disease Risk Factor Survey, an estimated 4.5 million Ugandan adults have hypertension. [19,20] 273 Given the high prevalence, a reanalysis of these distribution guidelines would be prudent. 274
Limiting the supply of anti-hypertensive medicines to higher level health facilities is incongruent 275 with the provision of high quality, chronic care for persons with hypertension. Lower level health 276 facilities, where the population is expected to receive primary health care, should be expected to 277 stock EM for NCDs such as hypertension. 278
279
There is also evidence of clear regional disparities in EM-NCD. While the West region is not 280 significantly different from the Kampala region, facilities in the North and the East have 281 significantly lower counts of EM-NCD than those in Kampala, even controlling for other 282 predictors of availability. On average and adjusting for the other predictors, facilities in the North 283 have scores 34% lower and those in the East have scores 38% lower than facilities in the 284 Kampala region. One possible explanation is that the supply routes running East-West are of 285 higher quality than those running North-South. However, in recent years, the Ugandan highway 286 infrastructure has improved greatly and there are equally high quality highways spanning East-287
West as there are North-South. Certainly, further research is warranted towards understanding 288 such in-country regional disparities. 289 290 Finally, the two HIV-related findings deserve special attention. We initially hypothesized that the 291 availability of services for communicable diseases such as HIV/AIDS might be diverting 292 resources and attention away from NCDs, resulting in lower average counts for facilities with 293 HIV/AIDS services. However, the preferred model suggests a more complex set of 294 interrelationships between HIV/AIDS services and the availability of EM-NCD. As 295 hypothesized, offering HIV care and support services was associated with lower average NCD 296 medicines counts. But offering HIV counseling and testing (HCT) was associated with higher 297 counts of NCD essential medicines. It is plausible that facilities that are able to offer HCT have 298 dispensary managers who are more attuned to the need to maintain chronic disease medicines. Or 299 possibly these facilities have more sophisticated processes in place for monitoring and 300 replenishing their medicine stock. Certainly, this is a result that we find compelling and in need 301 of further study. 302 303 SARA data are collected using a complex, non-representative sampling strategy that must be 304 corrected for using sample weights. In addition, SARA sample sizes are neither intentionally, nor 305 necessarily, powered to provide significant estimates in regression models. This has been an 306 impediment to wider use of these important data. Both the openly available country SARA 307 reports and all prior published research using SARA data have relied only on descriptive 308 statistics, reporting simple unadjusted proportions rather than associations. We have shown that, 309 despite these perceived barriers, researchers can use SARA data to develop regression models by 310 applying straightforward corrections and diagnostic checks. By conducting the first Poisson 311 analysis using SARA data, we have identified multiple disparities in availability of EM-NCD 312 within Uganda. 313 314 Our approach had some limitations. First, like any cross-sectional design, ours is unable to infer 315 causality. Longitudinal research is needed to better understand the sources of availability 316 disparities like those we describe. Second, the SARA tool does not collect data on EM cost, 317 thereby limiting its utility for directly addressing access, which is a function of both availability 318 and cost. Further, like other EM availability surveys, SARA data reflect stock on the pharmacy 319 shelf on a single day. This approach fails to account for variability in stock over time, which 320 could be substantial and might particularly influence estimates of geographic disparity. Finally, 321 though the public-facing data summary was available via the WHO[21], obtaining the raw 322 dataset for analysis was challenging. These limitations point to the unmet need for technologies 323 that provide real-time, hyper-local data to help spotlight and redress disparities in access faster --324 and to map, measure and monitor disparities in access to care. Overlaying such insights with 325 disease prevalence, population density, and health determinants such as traffic patterns and 326 household income would further increase utility for decision-makers. 327
328
To deepen our understanding of variation in EM-NCD availability within LMIC, future research 329 should aim to understand facility-and system-level barriers and facilitators to EM-NCD 330 availability. As more LMIC conduct SARA surveys, these datasets represent a largely untapped 331 empirical resource for global health researchers and policymakers. We demonstrate that data 332 generated by the SARA tool may be used to generate a robust, informative statistical model by 333 applying well-recognized techniques to correct for some of the most common challenges 334 inherent in these data. The results of such analyses can guide operational research and inform 335 decision-making, investment, and priority-setting. 336 337 338 339 340 341
Supplemental Analyses 342 343 Given the complex sampling strategy and the possibility that health facilities in the same district 344 may influence one another with regard to availability of EM-NCD, we also fit a multilevel mixed 345 model to supplement our primary analysis. There was little evidence of need for a multilevel 346 model and the parameter estimates of the multilevel mixed model were in general agreement 347 with those of the easier-to-interpret Poisson model presented in the main analysis. 348
349
We also considered an alternative model including the presence of other essential medicines as a 350 predictor, which was rejected because of evidence of serious multicollinearity .  351   352  353  354  355  356  357  358  359  360  361  362  363  364  365  366  367  368  369  370  371  372  373 
